BiPar like deal for TLN
https://www.reuters.com/article/rbssHealthcareNews/idUSN2332718920090423
Under the agreement, the purchase price will depend on theachievement of milestone payments related to the development ofBiPar's leading drug candidate, BSI-201, and could reach amaximum of $500 million, the two companies said on April 15.(Reporting by Diane Bartz, editing by Dave Zimmerman).
One aspect of deal making is that talks could break off because interests are divergeant.
Would be best long term if TLN gets a lucrative Licensing deal like Exelixis 200M - upfront payment, milestones payment and future profit sharing.
Takeover is nice too, no risk take the money and go away.
However, talks could end if parties are pushing in different direction. Also, another negative element would be unwillingness to assume clinical risk. Well, I am talking about the pending preliminary PIIa GBM trial that could be a hurdle to talks.
This phenomena is called : no one wanting to pull the trigger first...
Well, well... I have yet another positive fact that increases odd of a takeover!!!
The BiPar deal !
It's kind of a hybrid deal where, price is set condition to certain milestone achievement ie pending clinical results.
So it's a licensing-takeover deal!
Buyer will offer a base floar price and increase it accordingly to test results.
Awesome idea.
Convergeance of interest is hence practically inevitable.
Convergeance of interest = deal.
Another, positive fact to consider.
PS:
But wait Pepmoron wants to talk about MYG or LAB or some other unrelated issue. Let's not talk about TLN or Iressa or Tarceva or whatever is related to the oncology deal trend. No let's talk about something completed irrelevant. Pepmoron is the most stupid moron ever !
Wait, Pepmoron is going to say that BiPar cannot be compared with TLN. Somehow Sanofi isn't a pharma, BIpar isn't early stage but a late stage. Test results are inconclusive. That Roche isn't owner of Tarceva. AstraZeneca isn't a known company or that MYG will rise to 15$.